FDA IND clearance enables a phase 1b evaluation of SP16 in chemotherapy-induced pain and peripheral neuropathy, with enrollment planned for mid-2026 at the University of Virginia. Proposed mechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results